HTX-L01 003
Alternative Names: HTX-L01-003; ttLNP-BiTE mRNA - Hopewell TherapeuticsLatest Information Update: 14 May 2024
At a glance
- Originator Hopewell Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Lipids; Recombinant fusion proteins; RNA
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 08 May 2024 Pharmacodynamics data from a preclinical study in Solid tumours released by Hopewell Therapeutics
- 03 Nov 2023 Hopewell Therapeutics has patent protection for LNP technology in USA before November 2023 (Hopewell Therapeutics, November 2023 )
- 03 Nov 2023 Preclinical trials in Haematological malignancies in USA (IV)